MedTrace Logo

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

NCT02325414 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-02

Study results available
· View outcomes & findings →

Summary

The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.

Conditions

  • Spinal Cord Injury
  • Acute Spinal Cord Injury
  • Bone Loss
  • Osteoporosis

Interventions

DRUG

Zoledronic acid

Intravenous infusion of zoledronic acid 5 mg.

DRUG

Placebo

Placebo (saline) infusion to match zoledronic acid

Sponsors & Collaborators

Principal Investigators

  • Thomas J Schnitzer, MD, PhD · Northwestern University Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2020-08-25
Completion
2020-08-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02325414 on ClinicalTrials.gov